Occurrence of AKI | Without Primary Endpoint | With Primary Endpoint | ||||
---|---|---|---|---|---|---|

SARS-CoV, n=1148 | SARS-CoV-2, n=759 | P value | SARS-CoV, n=417 | SARS-CoV-2, n=55 | P value | |

Peak creatinine level median (range) | 83 (73–96) | 81 (68–95) | 0.001 | 101 (81–177) | 89 (76–119) | 0.06 |

No AKI, n (%) | 1083 (94.3) | 707 (93.1) | 0.04 | 268 (64.3) | 41 (74.5) | 0.07 |

AKI stage 1, n (%) | 55 (4.8) | 49 (6.5) | 68 (16.3) | 5 (9.1) | ||

AKI stage 2, n (%) | 3 (0.3) | 3 (0.4) | 30 (7.2) | 0 (0) | ||

AKI stage 3, n (%) | 7 (0.6) | 0 (0) | 51 (12.2) | 9 (16.4) | ||

Without ICU admission | With ICU admission | |||||

SARS-CoV, n=1240 | SARS-CoV-2, n=761 | P value | SARS-CoV, n=325 | SARS-CoV-2, n=53 | P value | |

Peak creatinine level median (range) | 84 (73–99) | 81 (68–95) | <0.001 | 97 (80–144) | 88 (75–118) | 0.12 |

No AKI, n (%) | 1128 (91.0) | 708 (93.0) | 0.003 | 223 (68.6) | 40 (75.5) | 0.11 |

AKI stage 1, n (%) | 82 (6.6) | 50 (6.6) | 41 (12.6) | 4 (7.5) | ||

AKI stage 2, n (%) | 10 (0.8) | 3 (0.4) | 23 (7.1) | 0 (0) | ||

AKI stage 3, n (%) | 20 (1.6) | 0 (0) | 38 (11.7) | 9 (17.0) | ||

Without invasive mechanical ventilation | With invasive mechanical ventilation | |||||

SARS-CoV, n=1504 | SARS-CoV-2, n=792 | P value | SARS-CoV, n=61 | SARS-CoV-2, n=22 | P value | |

Peak creatinine level median (range) | 86 (74–102) | 81 (68–95) | <0.001 | 109 (87–181) | 88 (77–315) | 0.24 |

No AKI, n (%) | 1319 (87.7) | 734 (92.7) | <0.001 | 32 (52.5) | 14 (63.6) | 0.41 |

AKI stage 1, n (%) | 112 (7.4) | 51 (6.4) | 11 (18.0) | 3 (13.6) | ||

AKI stage 2, n (%) | 26 (1.7) | 3 (0.4) | 7 (11.5) | 0 (0) | ||

AKI stage 3, n (%) | 47 (3.1) | 4 (0.5) | 11 (18.0) | 5 (22.7) | ||

Survival | Death | |||||

SARS-CoV, n=1398 | SARS-CoV-2, n=810 | P value | SARS-CoV, n=167 | SARS-CoV-2, n=4 | P value | |

Peak creatinine level median (range) | 84 (73–98) | 81 (68–95) | <0.001 | 161 (104–289) | 332 (117–595) | 0.31 |

No AKI, n (%) | 1290 (92.3) | 747 (92.2) | 0.27 | 61 (36.5) | 1 (25.0) | 0.81 |

AKI stage 1, n (%) | 77 (5.5) | 53 (6.5) | 46 (27.5) | 1 (25.0) | ||

AKI stage 2, n (%) | 13 (0.9) | 3 (0.4) | 20 (12.0) | 0 (0) | ||

AKI stage 3, n (%) | 18 (1.3) | 7 (0.9) | 40 (24.0) | 2 (50.0) |

A total of 20 patients who received RRT at diagnosis of SARS-CoV were not included in the analysis.

Primary endpoint was a composite endpoint of ICU admission, use of invasive mechanical ventilation, and/or death. Baseline creatinine level was on the basis of the creatinine level before or upon hospital admission. Peak creatinine level was presented in median (range). Qualitative and quantitative differences between subgroups were analyzed by chi-squared or Fisher’s exact tests for categorical parameters and Mann–Whitney

*U*test for continuous parameters, as appropriate.